Logo image of EHAB

ENHABIT INC (EHAB) Stock Fundamental Analysis

NYSE:EHAB - New York Stock Exchange, Inc. - US29332G1022 - Common Stock - Currency: USD

10.8  +0.04 (+0.37%)

After market: 10.8 0 (0%)

Fundamental Rating

3

Taking everything into account, EHAB scores 3 out of 10 in our fundamental rating. EHAB was compared to 102 industry peers in the Health Care Providers & Services industry. EHAB has a bad profitability rating. Also its financial health evaluation is rather negative. EHAB is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

EHAB had positive earnings in the past year.
EHAB had a positive operating cash flow in the past year.
In multiple years EHAB reported negative net income over the last 5 years.
EHAB had a positive operating cash flow in each of the past 5 years.
EHAB Yearly Net Income VS EBIT VS OCF VS FCFEHAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

1.2 Ratios

EHAB has a Return On Assets of -11.21%. This is in the lower half of the industry: EHAB underperforms 78.43% of its industry peers.
EHAB has a Return On Equity of -25.52%. This is in the lower half of the industry: EHAB underperforms 66.67% of its industry peers.
The Return On Invested Capital of EHAB (3.58%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for EHAB is significantly below the industry average of 9.59%.
Industry RankSector Rank
ROA -11.21%
ROE -25.52%
ROIC 3.58%
ROA(3y)-7%
ROA(5y)-1.92%
ROE(3y)-15.77%
ROE(5y)-6.79%
ROIC(3y)3.74%
ROIC(5y)4.76%
EHAB Yearly ROA, ROE, ROICEHAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

EHAB's Operating Margin of 4.80% is in line compared to the rest of the industry. EHAB outperforms 58.82% of its industry peers.
In the last couple of years the Operating Margin of EHAB has declined.
With a decent Gross Margin value of 48.97%, EHAB is doing good in the industry, outperforming 77.45% of the companies in the same industry.
In the last couple of years the Gross Margin of EHAB has remained more or less at the same level.
Industry RankSector Rank
OM 4.8%
PM (TTM) N/A
GM 48.97%
OM growth 3Y-29.61%
OM growth 5Y-4.28%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.12%
GM growth 5Y-1.19%
EHAB Yearly Profit, Operating, Gross MarginsEHAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EHAB is destroying value.
Compared to 1 year ago, EHAB has more shares outstanding
EHAB has a worse debt/assets ratio than last year.
EHAB Yearly Shares OutstandingEHAB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
EHAB Yearly Total Debt VS Total AssetsEHAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 1.64, we must say that EHAB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EHAB (1.64) is worse than 61.76% of its industry peers.
EHAB has a debt to FCF ratio of 9.89. This is a negative value and a sign of low solvency as EHAB would need 9.89 years to pay back of all of its debts.
EHAB has a Debt to FCF ratio of 9.89. This is comparable to the rest of the industry: EHAB outperforms 48.04% of its industry peers.
EHAB has a Debt/Equity ratio of 0.86. This is a neutral value indicating EHAB is somewhat dependend on debt financing.
EHAB has a Debt to Equity ratio of 0.86. This is comparable to the rest of the industry: EHAB outperforms 42.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 9.89
Altman-Z 1.64
ROIC/WACC0.41
WACC8.63%
EHAB Yearly LT Debt VS Equity VS FCFEHAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 500M 1B

2.3 Liquidity

EHAB has a Current Ratio of 1.49. This is a normal value and indicates that EHAB is financially healthy and should not expect problems in meeting its short term obligations.
EHAB has a Current ratio of 1.49. This is comparable to the rest of the industry: EHAB outperforms 52.94% of its industry peers.
A Quick Ratio of 1.49 indicates that EHAB should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.49, EHAB is in line with its industry, outperforming 56.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 1.49
EHAB Yearly Current Assets VS Current LiabilitesEHAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

EHAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite impressive.
The Revenue has decreased by -1.08% in the past year.
Measured over the past years, EHAB shows a decrease in Revenue. The Revenue has been decreasing by -1.07% on average per year.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)-1.08%
Revenue growth 3Y-2.21%
Revenue growth 5Y-1.07%
Sales Q2Q%-0.95%

3.2 Future

EHAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.22% yearly.
Based on estimates for the next years, EHAB will show a small growth in Revenue. The Revenue will grow by 5.89% on average per year.
EPS Next Y112.74%
EPS Next 2Y62.45%
EPS Next 3Y43.23%
EPS Next 5Y9.22%
Revenue Next Year2.56%
Revenue Next 2Y3.76%
Revenue Next 3Y3.95%
Revenue Next 5Y5.89%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EHAB Yearly Revenue VS EstimatesEHAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B
EHAB Yearly EPS VS EstimatesEHAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 0.5 1

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 45.00, EHAB can be considered very expensive at the moment.
EHAB's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.52, EHAB is valued quite expensively.
With a Price/Forward Earnings ratio of 19.49, EHAB is valued on the expensive side.
61.76% of the companies in the same industry are more expensive than EHAB, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.25, EHAB is valued at the same level.
Industry RankSector Rank
PE 45
Fwd PE 19.49
EHAB Price Earnings VS Forward Price EarningsEHAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EHAB indicates a somewhat cheap valuation: EHAB is cheaper than 61.76% of the companies listed in the same industry.
EHAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EHAB is cheaper than 86.27% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.05
EV/EBITDA 12.53
EHAB Per share dataEHAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

EHAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EHAB's earnings are expected to grow with 43.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y62.45%
EPS Next 3Y43.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EHAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENHABIT INC

NYSE:EHAB (6/6/2025, 8:04:00 PM)

After market: 10.8 0 (0%)

10.8

+0.04 (+0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners101.3%
Inst Owner ChangeN/A
Ins Owners2.71%
Ins Owner Change15.79%
Market Cap546.91M
Analysts76.36
Price Target10.46 (-3.15%)
Short Float %2.53%
Short Ratio3.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.43%
Min EPS beat(2)-28.32%
Max EPS beat(2)53.19%
EPS beat(4)2
Avg EPS beat(4)7.71%
Min EPS beat(4)-28.32%
Max EPS beat(4)53.19%
EPS beat(8)4
Avg EPS beat(8)11.92%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.27%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)-2.3%
Revenue beat(4)0
Avg Revenue beat(4)-3.98%
Min Revenue beat(4)-4.98%
Max Revenue beat(4)-2.3%
Revenue beat(8)0
Avg Revenue beat(8)-4.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.89%
PT rev (3m)15.17%
EPS NQ rev (1m)35.07%
EPS NQ rev (3m)49.32%
EPS NY rev (1m)14.76%
EPS NY rev (3m)49.78%
Revenue NQ rev (1m)-0.78%
Revenue NQ rev (3m)-1.29%
Revenue NY rev (1m)-0.64%
Revenue NY rev (3m)-1.01%
Valuation
Industry RankSector Rank
PE 45
Fwd PE 19.49
P/S 0.53
P/FCF 11.05
P/OCF 10.56
P/B 1.01
P/tB N/A
EV/EBITDA 12.53
EPS(TTM)0.24
EY2.22%
EPS(NY)0.55
Fwd EY5.13%
FCF(TTM)0.98
FCFY9.05%
OCF(TTM)1.02
OCFY9.47%
SpS20.39
BVpS10.73
TBVpS-8.1
PEG (NY)0.4
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.21%
ROE -25.52%
ROCE 4.53%
ROIC 3.58%
ROICexc 3.71%
ROICexgc 38.68%
OM 4.8%
PM (TTM) N/A
GM 48.97%
FCFM 4.8%
ROA(3y)-7%
ROA(5y)-1.92%
ROE(3y)-15.77%
ROE(5y)-6.79%
ROIC(3y)3.74%
ROIC(5y)4.76%
ROICexc(3y)3.81%
ROICexc(5y)4.84%
ROICexgc(3y)39.56%
ROICexgc(5y)58.49%
ROCE(3y)4.73%
ROCE(5y)6.02%
ROICexcg growth 3Y-27.94%
ROICexcg growth 5YN/A
ROICexc growth 3Y-21.68%
ROICexc growth 5YN/A
OM growth 3Y-29.61%
OM growth 5Y-4.28%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.12%
GM growth 5Y-1.19%
F-Score4
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 9.89
Debt/EBITDA 5.87
Cap/Depr 7.67%
Cap/Sales 0.22%
Interest Coverage 1.24
Cash Conversion 65.08%
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 1.49
Altman-Z 1.64
F-Score4
WACC8.63%
ROIC/WACC0.41
Cap/Depr(3y)51.64%
Cap/Depr(5y)35.82%
Cap/Sales(3y)1.58%
Cap/Sales(5y)1.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y112.74%
EPS Next 2Y62.45%
EPS Next 3Y43.23%
EPS Next 5Y9.22%
Revenue 1Y (TTM)-1.08%
Revenue growth 3Y-2.21%
Revenue growth 5Y-1.07%
Sales Q2Q%-0.95%
Revenue Next Year2.56%
Revenue Next 2Y3.76%
Revenue Next 3Y3.95%
Revenue Next 5Y5.89%
EBIT growth 1Y34.42%
EBIT growth 3Y-31.17%
EBIT growth 5Y-5.31%
EBIT Next Year77.79%
EBIT Next 3Y25.2%
EBIT Next 5YN/A
FCF growth 1Y86.09%
FCF growth 3Y-26.15%
FCF growth 5Y0%
OCF growth 1Y-24.16%
OCF growth 3Y-25.39%
OCF growth 5Y-2.96%